Evidence map›Paper›PMID 38432480›Full record

ArticleJournal of the American Pharmacists Association : JAPhA

Effect of pregabalin initiation on diuretic requirements in patients with chronic heart failure.

Avital Basri, Meredith A Sigler, Kevin C Kelly, Dawn H Lopez, Carlos A Alvarez

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Pharmacists Association : JAPhA. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Avital Basri
Meredith A Sigler
Kevin C Kelly
Dawn H Lopez
Carlos A Alvarez
Texas Tech University · USVA Heart of Texas Health Care Network · US

Funding

UT Southwestern Center for Translational MedicineUL1TR003163 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2021 to 2025
$39.3M
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
NCATS NIH HHS UL1 TR001105NCATS NIH HHS UL1 TR003163
6 · The paper itself

Abstract

backgroundLiterature on pregabalin use in patients with heart failure is largely limited to patient case reports and cohort studies.

objectiveThis study aimed to evaluate the effect of pregabalin initiation on diuretic requirements in patients with heart failure.

methodsA retrospective analysis of patients with heart failure who were started on pregabalin between January 1, 2014, and September 1, 2021, at the Veterans Affairs North Texas Health Care System was used. The primary objective was to determine the median change in loop diuretic dose, in furosemide dose equivalents, 6 months after pregabalin initiation.

resultsOf 58 patients analyzed, there was no statistically significant difference in the primary outcome (P = 0.162). The secondary outcomes were found to be nonstatistically significant, and there was no correlation between pregabalin dose and outcomes.

conclusionThis represents the largest analysis of diuretic dose requirements in patients with heart failure after initiation of pregabalin. Although there was no difference in the median change of diuretic dose prescribed, pregabalin should still be used with caution.

Indexed as

Heart FailurePregabalinAgedAged, 80 and overChronic DiseaseDiureticsDose-Response Relationship, DrugFemaleFurosemideHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsTexasDiureticsFurosemidePregabalinSodium Potassium Chloride Symporter Inhibitors

Identifiers

PMID38432480
PMCPMC11322954
OpenAlexW4392347106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.